Trials / Completed
CompletedNCT01001468
Study to Assess VB-201 in Patients With Psoriasis
A Randomized, Double-Blind, 12-Week, Dose-Ranging Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral VB-201 in Patients With Moderate to Severe Plaque Psoriasis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 185 (actual)
- Sponsor
- Vascular Biogenics Ltd. operating as VBL Therapeutics · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to examine the efficacy, safety and tolerability of VB-201 as compared with placebo on measures of disease activity in patients with psoriasis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | VB-201 | Single daily dose of oral VB-201 20 mg |
| DRUG | VB-201 | Single daily dose or oral VB-201 80 mg |
| OTHER | Placebo | Single daily dose of oral placebo |
Timeline
- Start date
- 2009-12-01
- Primary completion
- 2011-07-01
- Completion
- 2011-07-01
- First posted
- 2009-10-26
- Last updated
- 2011-11-16
Locations
18 sites across 3 countries: United States, Germany, Israel
Source: ClinicalTrials.gov record NCT01001468. Inclusion in this directory is not an endorsement.